Antitumor effects and anticancer applications of bisphosphonates

Area of Science:

• Oncology
• Pharmacology
• Bone Metastasis Research

Background:

• Bisphosphonates are standard for treating bone metastases in breast cancer, prostate cancer, and myeloma.
• Emerging evidence suggests bisphosphonates possess direct antitumor activity, potentially preventing bone metastasis.
• Mechanisms include apoptosis induction, inhibition of tumor cell adhesion/invasion, and anti-angiogenesis.

Purpose of the Study:

• To review preclinical and clinical evidence supporting the antitumor effects of bisphosphonates.
• To assess the potential of bisphosphonates in cancer treatment beyond bone disease management.
• To highlight the role of next-generation bisphosphonates in cancer therapy.

Main Methods:

• Systematic review of preclinical studies investigating bisphosphonate mechanisms.
• Analysis of clinical trial data on bisphosphonate efficacy in various cancer types.
• Evaluation of evidence for direct and indirect antitumor activities.

Main Results:

• Preclinical data support bisphosphonate-induced apoptosis, reduced invasion, and anti-angiogenesis.
• Nitrogen-containing bisphosphonates may enhance cytotoxic agent efficacy.
• Clinical data are limited and conflicting, often using older bisphosphonate generations.

Conclusions:

• Bisphosphonates show promise for direct antitumor effects and prevention of bone metastasis.
• Next-generation bisphosphonates, like zoledronic acid, require further clinical validation.
• Ongoing trials are crucial to confirm the expanded therapeutic role of bisphosphonates in oncology.